INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market purchaseVerified data

Giordano Christopher Thomas bought TENX

Director, CEO · TENAX THERAPEUTICS, INC. · Common Stock

Side
BUY
Value
$8,837
Shares
4,850
Price
$1.82
Executed
Sep 15, 2026
Disclosed
Sep 15, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Sep 15 executedSep 15, 2026 disclosed

TENX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
38/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+9 / 25

    $9K reported value · 28.0% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    4 prior trades recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TENX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    28
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$406K
    254.3K sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    28
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$551K
    332.0K sh
    		Oct 21, 2026Oct 21, 2026
    traded Oct 21, 2026
    		+0dSEC FORM 4

    Evidence

    32
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$507K
    336.5K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    42
    GT
    Giordano Christopher ThomasDirector, CEO
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$11K
    6,000 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    46
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$1.60M
    900.0K sh
    		Sep 3, 2026Sep 8, 2026
    traded Sep 3, 2026
    		+5dSEC FORM 4

    Evidence

    36
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$338K
    187.7K sh
    		Sep 2, 2026Sep 2, 2026
    traded Sep 2, 2026
    		+0dSEC FORM 4

    Evidence

    36
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$322K
    179.1K sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    40
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$723K
    403.6K sh
    		Aug 31, 2026Sep 2, 2026
    traded Aug 31, 2026
    		+2dSEC FORM 4

    Evidence

    38
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$1.27M
    716.4K sh
    		Aug 21, 2026Aug 24, 2026
    traded Aug 21, 2026
    		+3dSEC FORM 4

    Evidence

    28
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$188K
    107.4K sh
    		Aug 24, 2026Aug 24, 2026
    traded Aug 24, 2026
    		+0dSEC FORM 4

    Evidence

    39
    AM
    ADAR1 Capital Management, LLC10% Owner
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$360K
    202.1K sh
    		Aug 20, 2026Aug 24, 2026
    traded Aug 20, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HR
    Hunter RobynDirector
    TENXTENAX THERAPEUTICS, INC.
    Grant or award
    		A—
    30.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    5
    GT
    Giordano Christopher ThomasDirector, CEO
    TENXTENAX THERAPEUTICS, INC.
    Grant or award
    		A—
    450.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    5
    RS
    Rich StuartDirector, Chief Medical Officer
    TENXTENAX THERAPEUTICS, INC.
    Grant or award
    		A—
    250.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    DD
    Doogan DeclanDirector
    TENXTENAX THERAPEUTICS, INC.
    Grant or award
    		A—
    30.0K sh
    		Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    		+4dSEC FORM 4

    Evidence

    37
    RS
    Rich StuartDirector, Chief Medical Officer
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$25K
    2,500 sh
    		Dec 8, 2025Dec 10, 2025
    traded Dec 8, 2025
    		+2dSEC FORM 4

    Evidence

    37
    RS
    Rich StuartDirector, Chief Medical Officer
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$26K
    2,500 sh
    		Dec 9, 2025Dec 10, 2025
    traded Dec 9, 2025
    		+1dSEC FORM 4

    Evidence

    42
    RS
    Rich StuartDirector, Chief Medical Officer
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$14K
    1,500 sh
    		Dec 3, 2025Dec 5, 2025
    traded Dec 3, 2025
    		+2dSEC FORM 4

    Evidence

    42
    RS
    Rich StuartDirector, Chief Medical Officer
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$23K
    2,500 sh
    		Dec 4, 2025Dec 5, 2025
    traded Dec 4, 2025
    		+1dSEC FORM 4

    Evidence

    52
    RS
    Rich StuartDirector, Chief Medical Officer
    TENXTENAX THERAPEUTICS, INC.
    Open-market purchase
    		BUY$9,006
    1,000 sh
    		Dec 2, 2025Dec 5, 2025
    traded Dec 2, 2025
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001871714-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 15, 2026
    Published
    Sep 15, 2026
    Ingested by INSIDER
    Nov 5, 02:17 UTC
    Last re-read
    Nov 5, 02:17 UTC

    Extracted facts

    Filer
    Giordano Christopher Thomas
    Role
    Director, CEO
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    TENAX THERAPEUTICS, INC.
    Ticker
    TENX
    Shares
    4,850
    Price per share
    $1.82
    Value
    $8,837
    Execution date (reported)
    Sep 15, 2026
    Owned after transaction
    22.2K shares
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 4,850
    • Price: $1.8221

    = $8,837

    What this establishes

    Giordano Christopher Thomas filed this Form 4 reporting a open-market purchase of TENX on Sep 15, 2026. It became public on Sep 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO
    Giordano Christopher Thomascik:0001871714
    Issuer
    TENAX THERAPEUTICS, INC.cik:0000034956

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.